Immune checkpoint inhibition in <i>Epstein-Barr virus</i> associated gastric cancer: a case report highlighting the role of biomarker-driven treatment selection.

In the exploratory analysis of the phase III CheckMate 649 trial, although the limited sample size, patients with hypermutated tumors (n=31) derived the greatest OS benefit from chemoimmunotherapy (HR 0.37; 95% CI, 0.15-0.90) followed by EBV-positive tumors (n=34), which also showed a trend toward benefit from the addition of nivolumab to chemotherapy (HR 0.61; 95% CI, 0.26-1.45) [8.22].

also in 53,322 other papers